Advertisement

Olaparib Improves PFS in Phase III BRCA-Positive/HER2-Negative Breast Cancer Trial

Olaparib improved progression-free survival versus standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer, according to recent findings from the phase III OLYMPIAD trial.

 OncLive

click me